MarginsXMarginsX
Home › Markets › Health Care › MGRX

Mangoceuticals Inc. (MGRX)

MGRX trades on Nasdaq in Health Care, Misc Health and Biotechnology Services. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.1603
+3.42% on the day
Market cap
$3.6M
Nano cap
Revenue · 2025
$456K
-26.0% on 2024
Net income · 2025
-$20.6M
-4526.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1938046/000149315226014478/0001493152-26-014478-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMGRX on Nasdaq
SectorHealth Care
IndustryMisc Health and Biotechnology Services
CountryUnited States
IPO year2023
SEC CIK0001938046

Financials · 2025

LineValue
Revenue$456K
Net income-$20.6M
Operating income-$18.0M
Net margin-4526.8%
Operating margin-3954.3%
Revenue growth-26.0%
Cash$1.5M
Total assets$16.1M
P/E (computed)Net income was not positive
P/S (computed)7.8×

Warning signs

Cash runway
0.7 months
$229K cash at June 30, 2026
Share count, 1 year
+104.7%
2025-08-14 to 2026-08-13 · +1835.5% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
-$174K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These factors raise substantial doubt about the ability of the Company to continue as a going concern."
10-Q 2026-08-13
Cash and burn$229K cash; operating cash flow -$973K a quarter.Report 2026-06-30
Shares outstanding21,567,422 (2026-08-13); 10,535,791 a year earlier; 16,714,500 three years earlier. 3y figure adjusted for split (1-for-15 overall).Cover page 2026-08-13
Reverse splits, 3 years1; latest 1-for-15 on 2024-10-16Source 2024-10-16
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-10-09
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-02-06
AuditorTurner, Stone & Company, L.L.P., Dallas, Texas, United StatesPCAOB Form AP 2026-04-14
Late filings, 12 months2 NT noticesNT 10-Q 2026-05-15
Insider trades, 12 monthsBought $0, sold $174K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$69K-$1.3M-$261K$229K$45K$315K10-Q 2026-08-13
Q1 2026
2026-03-31
$68K-$3.4M-$1.3M$175KNo debt tags$415K10-Q 2026-05-19
Q4 2025
2025-12-31
$94K-$2.8M-$1.1M$1.5MNo debt tags$456K10-K 2026-04-01
Q3 2025
2025-09-30
$84K-$7.6M-$1.2M$481KNo debt tags$467K10-Q 2025-11-14
Q2 2025
2025-06-30
$168K-$5.4M-$1.3M$101KNo debt tags$516K10-Q 2026-08-13
Q1 2025
2025-03-31
$109K-$4.8M-$2.3M$76K$0$511K10-Q 2026-05-19
Q4 2024
2024-12-31
$105K-$1.9M-$1.1M$59K$150K$616K10-K 2026-04-01
Q3 2024
2024-09-30
$133K-$2.0M-$1.2M$74K$0$755K10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-20.5%
1 month-58.3%
3 months-70.9%
Year to date-79.1%
1 year-87.0%
From 52-week high-89.5%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Misc Health and Biotechnology Services

TickerCompanyPriceDayMarket cap
NIVFNewGenIvf Group Limited$0.2050-11.33%$2.0M
CCELCryo-Cell International Inc.$4.55-6.19%$36.7M
PARKPark Dental Partners Inc.$19.72-8.24%$109.2M
VMDViemed Healthcare Inc. Common Shares$9.15-0.22%$346.7M
AGLagilon health inc.$116.75+0.94%$2.0B
PGNYProgyny Inc.$37.15+2.68%$2.7B
SHCSotera Health Company$16.25-2.17%$4.6B
DVADaVita Inc.$174.22-0.19%$11.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier